

DAFTAR PUSTAKA

- American Cancer Society. Cancer Facts & Figures 2017. Atlanta: American Cancer Society; 2017.
- Apperley JF. Chronic myeloid leukemia. Lancet 2014.
- Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122(6):872-84.
- Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program. 2009:461-76.
- Breccia M, Binotto G. Bosutinib chronic myeloid leukemia. Rare Cancers Ther. 2015;3:35-46.
- Brunner AM, Campigotto F, Sadrzadeh H. Trends in All-Cause Mortality Among Patients With Chronic Myeloid Leukemia A Surveillance, Epidemiology, and End Results Database Analysis. Cancer. 2013; 2620-29
- Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood. 1982; 60: 1298-1304.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373–383.
- Chen R, Chen B. The role of dasatinib in the management of chronic myeloid leukemia. Drug, Design, Development and Therapy 2015; 9:773-9.
- Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L, et al. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic or

- accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. *Cancer* 2015; 121:1637-44.
- Cortes JE, Kim DW, Kantarjian HW, Brummendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial. *J Clin Oncol.* 2012; 30:3486-92.
- Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment naive chronic myeloid leukemia patients trial. *J Clin Oncol.* 2016.
- Doan V, Wang A, Prescott H. Bosutinib for the treatment of chronic myeloid leukemia. *Am J Health-Syst Pharm.* 2015; 72:439-47
- Deininger MWN, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. *Pharmacol Rev.* 2003; 55:401-23.
- Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med.* 2006;355:2408-17
- Faber E. Prognostic Scoring Systems in CML – Improvement Impossible? *J Leuk.* 2015; S1: 001
- Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. *The New England journal of medicine.* 1999; 341(3):164–172.
- Gandhi V, Plunkett W, Cortes JE. Omacetaxine: A protein translation inhibitor for treatment of chronic myelogenous leukemia. *Clin Cancer Res.* 2014; 20(7):1735-40
- Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM. Chronic myelogenous leukemia: A review and update of therapeutic strategies. *Cancer* 2003; 98(3):437-57.

- Harnicar S, Mathew S. Spotlight on nilotinib in the treatment of chronic myelogenous leukemia. *Blood and Lymphatic Cancer: Targets and Therapy* 2014;4:61-7.
- Hasford J, Ansari H, Pffrmann M, Hehlmann R. Analysis and validation of prognostic factors for CML. German CML Study Group. *Bone Marrow Transplant*. 2011; 17 Suppl 3: S49-54.
- Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. *Blood*. 2011; 118: 686-692.
- Hasford J, Pffrmann M, Hehlmann R, Allan NC, Baccarani M, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. *J Natl Cancer Inst*. 1998; 90: 850-858.
- Hehlman R, *Chronic Myeloid Leukemia, Germany*, 2016
- Henkes M, van der Kuip H, Aulitzky WE. Therapeutic options for chronic myeloid leukemia: Focus on imatinib *Therapeutics and Clinical Risk Management* 2008; 4(1):163-87.
- Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. *Leukemia*. 2013; 27: 2016-2022.
- Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. *Cancer* 2012;118: 3123–3127.
- Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an

- analysis from the International Randomized Study of Interferon and STI571 (IRIS). *Blood*. 2010; 116(19):3758–3765.
- Hughes TP, Ross M, Melo JV, Handbook Of Chronic Myeloid Leukemia. Australia: Adis, 2014.
- Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA and Hochhaus A: Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. *Blood* 123: 1353-1360, 2014.
- Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. *Chemotherapy Research and Practice* 2014.
- Jabbour E, Cortes J, Nazha A, O'Brien S, Quintas-Cardama A, et al. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. *Blood*. 2012; 119: 4524-4526.
- Jabbour E, Cortes J, Kantarjian H. Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. *Core Evidence* 2009;4:207-13.
- Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, monitoring, and management. *Am J Hematol*. 2018;93:442-59
- Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim D-W, Bradley-Garelik MB, Mohamed H, Wildgust M and Hochhaus A: Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). *Blood* 123: 494-500, 2014.

- Jain P, Kantarjian H, Ghorab A, et al. Prognostic factors and survival outcomes in patients with blast phase CML (CML-BP) in the tyrosine kinase inhibitor (TKI) era: cohort study of 477 patients. *Cancer*. 2017; 123(22): 4391–4402.
- Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. *J Clin Oncol*. 2011; 29(23):3173-8.
- Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. *Blood*. 2008; 112(8):3500-7.
- Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: An international, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2016;17(5):612-21
- Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. *Science*. 1990; 247(4946):1079–1082
- Marin D, Ibrahim AR and Goldman JM. European treatment and outcome Study (EutoS) score for chronic myeloid leukemia still requires more confirmation *J Clin Oncol*. 2012; 29(29) 3944–5.
- Melo JV, Hughes TP, Apperley JF. Chronic Myeloid Leukemia. *ASH Education Program Book*. 2003; 2003(1):132–152
- O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. *Curr Opin Genet Dev*. 2006; 16(1):92-9.
- Perotti D, Jamieson C, Goldman J. Chronic myeloid leukemia: mechanisms of blastic transformation. *J Clin Invest*. 2010; 120(7): 2254-64.

- Pfrrmann M, Lauseker M, Hoffmann VS, Hasford J. Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death. *Ann Hematol.* 1982; 94 Suppl 2: S209-218.
- Reksodiputro AH, Tadjoeidin H, Supandiman I, Acang N, Kar AS, Bakta IM, et al. Epidemiology study and mutation profile of patients with chronic myeloid leukemia (CML) in Indonesia. *J Blood Disord Transfus.* 2015;6:3.
- Sanford D, Kantarjian H, Skinner J, Jabbour E, Cortes J. Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. *Haematologica* 2015;100:494
- Saußele S, Krauß MP, Hehlmann R, Lauseker M, Proetel U, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. *Blood.* 2015; 126(1): 42–49.
- Shah NP. Loss of response to imatinib: mechanisms and management. *Hematology Am Soc Hematol Educ Program.* 2005:183-7.
- Skorski T. Genetic mechanisms of chronic myeloid leukemia blastic transformation. *Curr Hematol Malig Rep.* 2012 Jun;7(2):87-93.
- Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. *Blood.* 1984; 63: 789-799.
- Soria JY, Lujan AHT, Herreral LA, et al. Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute – Mexico, from 2000 to 2016 *Cancer Medicine.* 2019; 8:2942–2949.
- Standar Prosedur Operasional (SPO). Pemeriksaan Darah Lengkap (alat otomatis). RSUD Dr. Soetomo 2017.
- Swerdlow SH, CE.Harris, NL., et al., editors. World Health Organization Classification of Tumors of Haematopoietics and Lymphoid Tissues. IARC Press: Lyon; 2008.

- Tao Z. EutoS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib *Leuk Res.* 2012; 38(9) 1030–5.
- Tohami T, Nagler A, Amariglio N. Laboratory tools for diagnosis and monitoring responses in patients with chronic myeloid leukemia. *IMAJ.* 2012;14:501-7.
- Tura S, Baccarani M, Corbelli G. Staging of chronic myeloid leukaemia. *Br J Haematol.* 1981; 47: 105-119.
- Waclaw J, Sacha T, Stoklosa T. Imatinib in the treatment of chronic myeloid leukemia: Current perspectives on optimal dose. *Blood and Lymphatic Cancer: Targets and Therapy* 2015;5:101-8.